Plasma phospholipid transfer protein , cholesteryl ester transfer protein and lecithin : cholesterol acyltransferase in end-stage renal disease ( ESRD )
暂无分享,去创建一个
A. Levin | L. Er | M. Copland | D. Murphy-Burke | P. Taylor | Rajinder S. Singh | A. Levin
[1] S. Blankenberg,et al. Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] A. I. Moretti,et al. HUMAN CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION ENHANCES THE MOUSE SURVIVAL RATE IN AN EXPERIMENTAL SYSTEMIC INFLAMMATION MODEL: A NOVEL ROLE FOR CETP , 2008, Shock.
[3] T. Montange,et al. Effect of Plasma Phospholipid Transfer Protein Deficiency on Lethal Endotoxemia in Mice* , 2008, Journal of Biological Chemistry.
[4] C. Carty,et al. Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. , 2008, The American journal of cardiology.
[5] M. Davidson,et al. High-density lipoprotein metabolism: potential therapeutic targets. , 2007, The American journal of cardiology.
[6] G. Kaysen. Hyperlipidemia in Chronic Kidney Disease , 2007, The International journal of artificial organs.
[7] S. Blankenberg,et al. Phospholipid Transfer Protein in Hemodialysis Patients , 2007, American Journal of Nephrology.
[8] D. Rader. Molecular regulation of HDL metabolism and function: implications for novel therapies. , 2006, The Journal of clinical investigation.
[9] J. Kastelein,et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[10] N. Vaziri. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. , 2006, American journal of physiology. Renal physiology.
[11] B. G. Brown,et al. Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. , 2006, Biochimica et biophysica acta.
[12] J. Kastelein,et al. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[13] M. Jauhiainen,et al. Determination of human plasma phospholipid transfer protein mass and activity. , 2005, Methods.
[14] A. Schlitt,et al. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. , 2005, Biochimica et biophysica acta.
[15] S. Tam,et al. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. , 2005, Atherosclerosis.
[16] Haifeng Guo,et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] N. Vaziri,et al. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. , 2004, American journal of physiology. Renal physiology.
[18] M. Navab,et al. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity Published, JLR Papers in Press, July 16, 2004. DOI 10.1194/jlr.M400053-JLR200 , 2004, Journal of Lipid Research.
[19] N. Vaziri. Oxidative stress in uremia: nature, mechanisms, and potential consequences. , 2004, Seminars in nephrology.
[20] Aldons J Lusis,et al. Thematic review series: The Pathogenesis of Atherosclerosis Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.R400001-JLR200 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL , 2004, Journal of Lipid Research.
[21] F. Gejyo,et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. , 2003, Kidney international.
[22] M. Togo,et al. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. , 2003, Atherosclerosis.
[23] S. Going,et al. Cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase activities in hispanic and anglo postmenopausal women: associations with total and regional body fat. , 2003, Metabolism: clinical and experimental.
[24] Peter Stenvinkel,et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.
[25] A. Tol. Phospholipid transfer protein. , 2002 .
[26] M. Jauhiainen,et al. The Mechanism of the Remodeling of High Density Lipoproteins by Phospholipid Transfer Protein* , 2001, The Journal of Biological Chemistry.
[27] F. Gejyo,et al. Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[28] N. Vaziri,et al. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. , 2001, Kidney international.
[29] M. Kamada,et al. Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody. , 2000, Journal of lipid research.
[30] N. Vaziri,et al. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[31] Tomoko Yamaguchi,et al. A cholesteryl ester transfer protein gene mutation and vascular disease in dialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.
[32] A. von Eckardstein,et al. Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre beta 1-HDL. , 1996, Biochimica et biophysica acta.
[33] S. Marcovina,et al. Molecular biology of phospholipid transfer protein , 1996, Current opinion in lipidology.
[34] M. Jauhiainen,et al. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. , 1993, The Journal of biological chemistry.
[35] T. Shoji,et al. Impaired metabolism of high density lipoprotein in uremic patients. , 1992, Kidney international.
[36] A. Tall,et al. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. , 1985, Journal of lipid research.
[37] J. Glomset,et al. The plasma lecithins:cholesterol acyltransferase reaction. , 1968, Journal of lipid research.